Tag: bill

  • Mistaken identity leads to big hospital bill mix-up : Shots

    Mistaken identity leads to big hospital bill mix-up : Shots

    In 2013, Grace E. Elliott spent a night in a hospital in Florida for a kidney infection that was treated with antibiotics. Eight years later, she got a large bill from the health system that bought the hospital. This bill was for an unrelated surgical procedure she didn’t need and never received. It was a case of mistaken identity, she knew, but proving that wasn’t easy.

    Shelby Knowles for KHN


    hide caption

    toggle caption

    Shelby Knowles for KHN


    In 2013, Grace E. Elliott spent a night in a hospital in Florida for a kidney infection that was treated with antibiotics. Eight years later, she got a large bill from the health system that bought the hospital. This bill was for an unrelated surgical procedure she didn’t need and never received. It was a case of mistaken identity, she knew, but proving that wasn’t easy.

    Shelby Knowles for KHN

    Earlier this year, Grace Elizabeth Elliott got a mysterious hospital bill for medical care she had never received.

    She soon discovered how far a clerical error can reach — even across a continent — and how frustrating it can be to fix.

    During a college break in 2013, Elliott, then 22, began to feel faint and feverish while visiting her parents in Venice, Fla., which is about an hour south of Tampa. Her mother, a nurse, drove her to a facility that locals knew simply as Venice Hospital.

    In the emergency department, Elliott was diagnosed with a kidney infection and held overnight before being discharged with a prescription for antibiotics, a common treatment for the illness.

    “My hospital bill was about $100, which I remember because that was a lot of money for me as an undergrad,” said Elliott, now 31.

    She recovered and eventually moved to California to teach preschool. Venice Regional Medical Center was bought by Community Health Systems, based in Franklin, Tenn., in 2014 and eventually renamed ShorePoint Health Venice.

    The kidney infection and overnight stay in the E.R. would have been little more than a memory for Elliott.

    Then another bill came.

    The Patients: Grace E. Elliott, 31, a preschool teacher living with her husband in San Francisco, and Grace A. Elliott, 81, a retiree in Venice, Fla.

    Medical Services: For Grace E., an emergency department visit and overnight stay, plus antibiotics to treat a kidney infection in 2013. For Grace A., a shoulder replacement and rehabilitation services in 2021.

    Service Provider: Venice Regional Medical Center, later renamed ShorePoint Health Venice.

    Total Bill: $1,170, the patient’s responsibility for shoulder replacement services, after adjustments and payments of $13,210.21 by a health plan with no connection to Grace E. Elliott. The initial charges were $123,854.14.

    What Gives: This is a case of mistaken identity, a billing mystery that started at a hospital registration desk and didn’t end until months after the file had been handed over to a collections agency.

    Early this year, Grace E. Elliott’s mother opened a bill from ShorePoint Health Venice that was addressed to her daughter and sought more than $1,000 for recent hospital services, Elliott said. She “immediately knew something was wrong.”

    Months of sleuthing eventually revealed that the bill was meant for Grace Ann Elliott, a much older woman who underwent a shoulder replacement procedure and rehabilitation services at the Venice hospital last year.

    Experts said that accessing the wrong patient’s file because of a name mix-up is a common error — but one for which safeguards, like checking a patient’s photo identification, usually exist.

    The hospital had treated at least two Grace Elliotts. When Grace A. Elliott showed up for her shoulder replacement, a hospital employee had pulled up Grace E. Elliott’s account by mistake.

    “This is the kind of thing that can definitely happen,” said Shannon Hartsfield, a Florida attorney who specializes in health care privacy violations. (Hartsfield does not represent anyone involved in this case.) “All kinds of human errors happen. A worker can pull up the names, click the wrong button, and then not check [the current patient’s] date of birth to confirm.”

    It was a seemingly obvious error: The younger Elliott was billed for a procedure she didn’t have by a hospital she had not visited in years. But it took her nearly a year of hours-long phone calls to undo the damage.

    At first, worried that she had been the victim of identity theft, Grace E. Elliott contacted ShorePoint Health Venice and was bounced from one department to another. At one point, a billing employee disclosed to Elliott the birthdate the hospital had on file for the patient who had the shoulder replacement — it was not hers. Elliott then sent the hospital a copy of her ID.

    It took weeks for an administrator at ShorePoint’s corporate office in Florida to admit the hospital’s error and promise to correct it.

    In August, though, Grace E. Elliott received a notice that the corporate office had sold the debt to a collections agency called Medical Data Systems. Even though the hospital had acknowledged its error, the agency was coming after Grace E. Elliott for the balance due for Grace A. Elliott’s shoulder surgery.

    “I thought, ‘Well, I’ll just work with them directly,’” Grace E. Elliott said.

    Her appeal was denied. Medical Data Systems said in its denial letter that it had contacted the hospital and confirmed the name and address on file. The agency also included a copy of Grace A. Elliott’s expired driver license to Grace E. — along with several pages of the older woman’s medical information — in support of its conclusion.

    “A collection agency, as a business associate of a hospital, has an obligation to ensure that the wrong patient’s information is not shared,” Hartsfield said.

    In an email to KHN, Cheryl Spanier, a vice president of the collections agency wrote that “MDS follows all state and federal rules and regulations.” Spanier declined to comment on Elliott’s case, saying she needed the written consent of both the health system and the patient to do so.

    Elliott’s second appeal was also denied. She was told to contact the hospital to clear up the issue. But because the health system had long since sold the debt, Elliott said, she got no traction in trying to get ShorePoint Health Venice to help her. The hospital closed in September.

    Resolution: In mid-November, shortly after a reporter contacted ShorePoint Health, which operates other hospitals and facilities in Florida, Grace E. Elliott received a call from Stanley Padfield, the Venice hospital’s outgoing privacy officer and director of health information management. “He said, ‘It’s taken care of,’ ” Elliott said, adding that she was relieved but skeptical. “I’ve heard that over and over.”

    Elliott said Padfield told her that she had become listed as Grace A. Elliott’s guarantor, meaning she was legally responsible for the debt of a woman she had never met.

    Elliott soon received a letter from Padfield stating that ShorePoint Health had removed her information from Grace A. Elliott’s account and confirmed that she had not been reported to any credit agencies. The letter said her information had been removed from the collection agency’s database and acknowledged that the hospital’s fix initially “was not appropriately communicated” to collections.

    Padfield said the error started with a “registration clerk,” who he said had “received additional privacy education as a result of this incident.”

    Devyn Brazelton, marketing coordinator for ShorePoint Health, told KHN the hospital believes the error was “an isolated incident.”

    Using the date of birth provided by a hospital worker, Elliott was able to contact Grace A. Elliott and explain the mix-up.

    “I’m a little upset right now,” Grace A. Elliott told KHN on the day she learned about the billing error and disclosure of her medical information.

    The Takeaway: Grace E. Elliott said that when she asked Padfield, the Venice hospital’s outgoing privacy officer, whether she could have done something to fight such an obvious case of mistaken identity, he replied, “Probably not.”

    This, experts said, is the dark secret of identity issues: Once a mistake has been entered into a database, it can be remarkably difficult to fix. And such incorrect information can live for generations.

    For patients, that means it’s crucial to periodically review the information on your patient portal — the online medical profile many providers use to manage things like scheduling appointments, organizing medical records, and answering patient questions.

    One downside of electronic medical records is that errors spread easily and repeat frequently. It is important to challenge and correct errors in medical records early and forcefully, with every bit of documentation available. That is true whether the problem is an incorrect name, a medication no longer (or never) taken, or an inaccurate diagnosis.

    The process of amending a record can be “very involved,” Hartsfield said. “But with patients able now to see more and more of their medical records, they are going to want those amendments, and health systems and their related entities need to get prepared for that.”

    Grace A. Elliott told KHN that she had received a call from ShorePoint Health in the previous few months indicating that she owed money for her shoulder replacement.

    She asked for a copy of the bill, she told KHN. Months after she asked, it still hadn’t arrived.

    KHN (Kaiser Health News) is a national, editorially independent program of KFF (Kaiser Family Foundation).

  • Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Hemp, Inc.

    Hemp, Inc.

    Las Vegas, NV, Nov. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWireHemp, Inc. (OTC PINK: HEMP): It’s a new dawn, a new day as the first bill solely related to marijuana is sent to POTUS after being approved by the U.S. House and Senate – an unfathomable feat a decade ago. Passed by unanimous consent, by the Senate, the marijuana-related bill signals times are changing and so are perceptions about marijuana.

    Too many lives have been upended because of our failed approach to marijuana.  It’s time that we right these wrongs. – President Joe Biden
    (Source: White House Briefing Room)

    After years of championing legislation to legalize marijuana for medical purposes, the H.R. 8454 – Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a “historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis.”

    In a statement released by U.S. Congressman Earl Blumenauer (Founder and Co-chair of the Congressional Cannabis Caucus and Sponsor of the Medical Marijuana and Cannabidiol (CBD)  Research Act), “The public is tired of waiting for the federal government to catch up. Nearly half of our nation’s population now live in states where adult-use of cannabis is legal. For far too long, Congress has stood in the way of science and progress, creating barriers for researchers attempting to study cannabis and its benefits. At a time when more than 155 million Americans reside where adult-use of cannabis is legal at the state or local level and there are four million registered medical marijuana users with many more likely to self-medicate, it is essential that we are able to fully study the impacts of cannabis use.” (Source)

    Per Congress.gov, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:

    Establish a new, separate registration process to facilitate research on marijuana.

    Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

    The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

    Finally, the bill includes various other provisions, including provisions that:
    ·       require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
    ·       prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
    ·       allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
    ·       require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. (Source: Congress.gov)

    In a nutshell, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will allow a more streamlined approach to the application process for marijuana studies and will remove the barriers that slowed down the process. Research on CBD and other potentially beneficial marijuana-derived substances will be based on sound science without any regulatory hindrance. Yes, there is evidence suggesting marijuana is beneficial in treating glaucoma and epilepsy.  But as Congressmen Andy Harris said, “Only scientific research will prove the veracity of the many claims regarding efficacy for other diseases. Despite lacking much scientific research, over three dozen states have already legalized medical marijuana, and the American public deserves to know the effect modern marijuana has on the human body.”

    When the bill officially reaches President Joe Biden’s desk, he will have 10 days (excluding Sundays) to sign or veto it.  A White House spokesperson confirmed President Biden intends on signing the legislation. Once it’s signed and enacted, the cannabis industry could see a flurry of marijuana-related bills.  MJ Biz Daily reported there are “roughly 50 marijuana-related bills circulating in Congress” with the SAFE Banking Act (a proposed law that will allow state-legal dispensaries to access banking services) expected to have the best chance of passage.  Congressman Blumenauer believes the upcoming enactment of the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act could provide the momentum needed to push it through Congress.

    Why is the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act significant? After numerous failed attempts from past bills, what propelled this one to the President’s desk for signature? It’s the first legislation to unite opponents and proponents of cannabis legalization. Both sides want extensive research done, albeit for different reasons nonetheless. (Source)

    According to an article in Cardinal News, opponents want evidence that marijuana is harmful and proponents want evidence that it’s useful for medical applications. A myriad of questions needs answers. Do we need a surgeon general’s warning? How can marijuana-derived medications treat various health conditions? These are just a couple of questions researchers have not been able to answer because marijuana is a Schedule 1 controlled substance with bureaucratic hurdles and security measures deterring “would-be researchers” from finding the answers.

    This won’t be the case much longer. A new dawn, a new day is here for federal cannabis reform. And as Bruce Perlowin (Hemp, Inc.’s Chief Visionary Consultant) said back in 2015, “you can’t hold back the tide”. Once the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act is signed into law by Biden, the door will be open for new, innovative treatments derived from cannabis that will, hopefully, give patients more treatment options, according to Senate Majority Leader Chuck Schumer.

    Until then, check out Hemp, Inc.’s product lines containing CBD, CBDA, CBG, CBGA, and CBN (non-psychoactive compounds found in cannabis plants). CBD, in particular, is known for pain relief, relaxation, and anxiety relief. Adding CBG to CBD is known to enhance pain relief and CBN is known for helping sleeplessness. When CBN is combined with CBD and CBG, the benefits include relaxation, and reduced anxiety and pain thereby aiding in a better night’s sleep. Hemp, Inc.’s product lines have received rave reviews due to the high potency and effective, real therapeutic dose. The company uses a pharmaceutical-grade beta-cyclodextrin (a carbohydrate used during the manufacturing process) which is combined with CBD and CBG for rapid absorption and uptake. To order these amazing products, click here.

    About Hemp, Inc.
    With more than 10 years of experience in growing and processing hemp in North America, Hemp, Inc. has an established network of industry professionals in every segment of the industrial hemp industry. Hemp, Inc.’s 85,000 square-foot facility on over 9 acres in Spring Hope, N.C. is one of the largest industrial multipurpose hemp processing facilities in North America. Its mission of providing green solutions that help make the world a better place continues to flourish as the company advances an ever-growing portfolio of revenue and value-generating synergistic businesses. Hemp may be the salvation in retooling America for greener, more sustainable domestic manufacturing.

    To catch up with the latest news on Hemp, Inc., be sure to check out:

    Hemp Inc.’s Year to Date Sales Increase 315{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} Over Last Year
    Hemp Inc. Reports Third Quarter Results and Removal of “Yield” Sign
    Hemp Inc. Reveals Stunning Results of its Hemp Research
    Hemp Inc. Applauds President Biden’s Plan to Pardon People Convicted of Simple Marijuana Possession
    Hempcrete Approved for U.S. Residential Construction
    Hemp Inc. See Significant Increase in Revenue Over the Last 3 Quarters
    Global Hemp Fiber Market Rising at an Annual Rate of 6.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    Hemp, Inc. Offers CBD-CBG Topical Pain Relief Roll-On
    Hemp, Inc.’s Chief Visionary Consultant Bruce Perlowin Brings Opportunity to Hemp, Inc. (August 8, 2022)
    Hemp Inc.’s CBDA and CBGA Products on Sale Now (July 19, 2022)
    Hemp Inc.’s Chief Visionary Consultant Bruce Perlowin talks with Stock Day podcast about Hemp Inc.’s super potent line of CBD/CBG/CBN Products (July 7, 2022)
    Healthy Products for Healthy Living: A Look into Hemp, Inc.’s Pure, Premium, and Potent CBD and Wellness Products (June 16, 2022)
    Hemp, Inc. Releases New High Potency CBD/CBG Vanilla Flavored Coffee Enhancer (June 9, 2022)
    Hemp, Inc.’s King of Hemp CBD-CBG-CBN Natural Sleep Aid Capsules in Stock and On Sale (May 26, 2022)
    King of Hemp Natural and Vanilla-Flavored CBD/CBG “Super” Tinctures Now in Stock (May 12, 2022)

    The Company will continue to keep its shareholders up to date on all pertinent material events, product releases, production plans, and inventory availability. Those interested in distributing on a large-scale basis should email [email protected] or call 877-436-7564 for more information. The entire product line includes tinctures, gummies, capsules, and edibles in a variety of sizes, potencies, flavors, and formulas with a future focus on healthy foods for healthy living.

    Forward-Looking Statements

    This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. The Securities and Exchange Commission (SEC) requires issuers to provide “adequate current information”. Financials for Hemp, Inc. are listed on the OTC Exchange. More information can also be found on the Hemp, Inc. website by visiting www.hempinc.com/hemp-financial-disclosures/. The material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks and uncertainties.

    Contact: Hemp, Inc.
    ir@hempinc.com / (855) 436-7688
    Sales:(877) 436-7564

  • Biden Signs Medical Marijuana Research Bill

    Biden Signs Medical Marijuana Research Bill

    President Joe Biden turns the Healthcare Marijuana Investigation Bill into regulation, modifying how American experts can do investigate on marijuana.

    As anticipated by Marijuana Minute very last 7 days, the White Property declared on Friday that President Biden signed the Health care Marijuana and Cannabidiol Study Enlargement Act, “which establishes a new registration approach for conducting investigate on marijuana and for manufacturing marijuana solutions for analysis purposes and drug growth.”

    The bipartisan invoice was launched in July, quickly passed in the Home in the identical thirty day period, and unanimously approved by the Senate in November.

    Rep. Earl Blumenauer (Democrat), who sponsored the invoice, launched a joint press statement along with Cannabis Caucus Co-Chairs Barbara Lee (Democrat), Dave Joyce (Republican), and Brian Mast (Republican) stressing the great importance of these accomplishment.

    “For decades, the federal governing administration has stood in the way of science and progress—peddling a misguided and discriminatory technique to cannabis. Now marks a monumental phase in remedying our federal hashish legal guidelines. The Professional medical Cannabis and Cannabidiol Research Expansion Act will make it a lot easier to analyze the impacts and probable of hashish,” the statement reads.

    Moreover, the Reps highlighted how elementary is healthcare analysis on marijuana to realize the comprehensive medicinal likely of the plant to treat a extensive array of medical problems and pledged to function on ending the war on medication via a sequence of approaching proposals that will reshape the position of marijuana at the federal amount.

    The regulation drastically eases the lives of researchers who would like to review cannabis for healthcare applications, as they had to stick to strict restrictions that could delay their research.

    The new legislation removes federal restrictions in buy to simplicity investigate from finding out the plant and speeds up the software process to approve marijuana-similar scientific scientific studies.

    Below the new legislation, the federal govt has to guarantee an adequate, uninterrupted offer of cannabis obtainable to researchers for studies on health-related marijuana.

    For that reason, researchers will be capable to find out extra about the plant’s clinical attributes and ask for large quantities of marijuana to use for analysis.

    In point, the legislation now needs that in 60 times of obtaining a researcher’s software, the U.S. Attorney Basic has to approve it, request a lot more facts, or deny it specifying the reasons. If scientists submit extra information on request, the Lawyer Common has 30 times to make your mind up.

    Universities and analysis establishments will now be ready to receive U.S. Drug Enforcement Administration (DEA) license to expand, manufacture, distribute, dispense and possess cannabis for investigate reasons, with advice from the Department of Well being and Human Expert services (HHS) and the U.S. Foods And Drug Administration.

    Scientists who would like to do cannabis investigation may perhaps update their protocol without having informing the DEA if the quantity and kind of cannabis, the supply, and the storage disorders of the product won’t alter.

    The laws also encourages the Fda to acquire marijuana-derived medications and addresses the HHS to identify the opportunity healthcare rewards of cannabis or cannabidiol (or CBD) as a drug.

    The Healthcare Cannabis and Cannabidiol Exploration Enlargement Act also intervenes in the doctor-affected individual relationship by allowing for medical professionals to focus on the at this time acknowledged possible harms and benefits of marijuana cannabinoids, such as CBD, as a therapy or the recognised doable damages and advantages of cannabis and its compounds.

    However, the legislation does not permit experts to get cannabis from point out-operate dispensaries and will not likely reschedule marijuana at the federal amount.

    In point, marijuana will continue to be unlawful at the federal stage underneath Routine I of the Managed Substances Act.

    However, the laws signifies a considerable action ahead for professional medical investigation on marijuana in the U.S.

    In advance of the new legislation, doing investigate on marijuana was really difficult in the U.S. as experts necessary acceptance from multiple agencies to perform experiments, which could sometimes choose yrs.

    Additionally, researchers were being only permitted to use marijuana developed by the College of Mississippi, even though the DEA has not too long ago awarded six other cannabis cultivation licenses for investigate to U.S. corporations.

    Biden’s signature of The Health-related Cannabis and Cannabidiol Study Growth Act follows the executive get in October pardoning about 6,500 persons convicted for cannabis possession at the federal degree.

    On that celebration, he also asked the Secretary of the HHS and the Attorney Common to “initiate the approach of examining how cannabis is scheduled less than federal legislation.”

    Though the new legislation doesn’t put into practice a lot more reform at the federal level, it may possibly pave the way for new federal legislation on cannabis, such as the Protected Banking Act, that may possibly relieve the federal limits on the cannabis industry.

  • Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

    Las Vegas, NV, Nov. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Hemp, Inc. (OTC PINK: HEMP): It’s a new dawn, a new day as the first bill solely related to marijuana is sent to POTUS after being approved by the U.S. House and Senate – an unfathomable feat a decade ago. Passed by unanimous consent, by the Senate, the marijuana-related bill signals times are changing and so are perceptions about marijuana.

    Too many lives have been upended because of our failed approach to marijuana.  It’s time that we right these wrongs. – President Joe Biden
    (Source: White House Briefing Room)

    After years of championing legislation to legalize marijuana for medical purposes, the H.R. 8454 – Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a “historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis.”

    In a statement released by U.S. Congressman Earl Blumenauer (Founder and Co-chair of the Congressional Cannabis Caucus and Sponsor of the Medical Marijuana and Cannabidiol (CBD)  Research Act), “The public is tired of waiting for the federal government to catch up. Nearly half of our nation’s population now live in states where adult-use of cannabis is legal. For far too long, Congress has stood in the way of science and progress, creating barriers for researchers attempting to study cannabis and its benefits. At a time when more than 155 million Americans reside where adult-use of cannabis is legal at the state or local level and there are four million registered medical marijuana users with many more likely to self-medicate, it is essential that we are able to fully study the impacts of cannabis use.” (Source)

    Per Congress.gov, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:

    Establish a new, separate registration process to facilitate research on marijuana.

    Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

    The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

    Finally, the bill includes various other provisions, including provisions that:
    ·       require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
    ·       prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
    ·       allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
    ·       require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. (Source: Congress.gov)

    In a nutshell, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will allow a more streamlined approach to the application process for marijuana studies and will remove the barriers that slowed down the process. Research on CBD and other potentially beneficial marijuana-derived substances will be based on sound science without any regulatory hindrance. Yes, there is evidence suggesting marijuana is beneficial in treating glaucoma and epilepsy.  But as Congressmen Andy Harris said, “Only scientific research will prove the veracity of the many claims regarding efficacy for other diseases. Despite lacking much scientific research, over three dozen states have already legalized medical marijuana, and the American public deserves to know the effect modern marijuana has on the human body.” 

    When the bill officially reaches President Joe Biden’s desk, he will have 10 days (excluding Sundays) to sign or veto it.  A White House spokesperson confirmed President Biden intends on signing the legislation. Once it’s signed and enacted, the cannabis industry could see a flurry of marijuana-related bills.  MJ Biz Daily reported there are “roughly 50 marijuana-related bills circulating in Congress” with the SAFE Banking Act (a proposed law that will allow state-legal dispensaries to access banking services) expected to have the best chance of passage.  Congressman Blumenauer believes the upcoming enactment of the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act could provide the momentum needed to push it through Congress.

    Why is the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act significant? After numerous failed attempts from past bills, what propelled this one to the President’s desk for signature? It’s the first legislation to unite opponents and proponents of cannabis legalization. Both sides want extensive research done, albeit for different reasons nonetheless. (Source)

    According to an article in Cardinal News, opponents want evidence that marijuana is harmful and proponents want evidence that it’s useful for medical applications. A myriad of questions needs answers. Do we need a surgeon general’s warning? How can marijuana-derived medications treat various health conditions? These are just a couple of questions researchers have not been able to answer because marijuana is a Schedule 1 controlled substance with bureaucratic hurdles and security measures deterring “would-be researchers” from finding the answers.

    This won’t be the case much longer. A new dawn, a new day is here for federal cannabis reform. And as Bruce Perlowin (Hemp, Inc.’s Chief Visionary Consultant) said back in 2015, “you can’t hold back the tide”. Once the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act is signed into law by Biden, the door will be open for new, innovative treatments derived from cannabis that will, hopefully, give patients more treatment options, according to Senate Majority Leader Chuck Schumer.

    Until then, check out Hemp, Inc.’s product lines containing CBD, CBDA, CBG, CBGA, and CBN (non-psychoactive compounds found in cannabis plants). CBD, in particular, is known for pain relief, relaxation, and anxiety relief. Adding CBG to CBD is known to enhance pain relief and CBN is known for helping sleeplessness. When CBN is combined with CBD and CBG, the benefits include relaxation, and reduced anxiety and pain thereby aiding in a better night’s sleep. Hemp, Inc.’s product lines have received rave reviews due to the high potency and effective, real therapeutic dose. The company uses a pharmaceutical-grade beta-cyclodextrin (a carbohydrate used during the manufacturing process) which is combined with CBD and CBG for rapid absorption and uptake. To order these amazing products, click here.

    About Hemp, Inc.
    With more than 10 years of experience in growing and processing hemp in North America, Hemp, Inc. has an established network of industry professionals in every segment of the industrial hemp industry. Hemp, Inc.’s 85,000 square-foot facility on over 9 acres in Spring Hope, N.C. is one of the largest industrial multipurpose hemp processing facilities in North America. Its mission of providing green solutions that help make the world a better place continues to flourish as the company advances an ever-growing portfolio of revenue and value-generating synergistic businesses. Hemp may be the salvation in retooling America for greener, more sustainable domestic manufacturing.

    To catch up with the latest news on Hemp, Inc., be sure to check out:

    Hemp Inc.’s Year to Date Sales Increase 315{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} Over Last Year
    Hemp Inc. Reports Third Quarter Results and Removal of “Yield” Sign
    Hemp Inc. Reveals Stunning Results of its Hemp Research
    Hemp Inc. Applauds President Biden’s Plan to Pardon People Convicted of Simple Marijuana Possession
    Hempcrete Approved for U.S. Residential Construction
    Hemp Inc. See Significant Increase in Revenue Over the Last 3 Quarters
    Global Hemp Fiber Market Rising at an Annual Rate of 6.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    Hemp, Inc. Offers CBD-CBG Topical Pain Relief Roll-On
    Hemp, Inc.’s Chief Visionary Consultant Bruce Perlowin Brings Opportunity to Hemp, Inc. (August 8, 2022)
    Hemp Inc.’s CBDA and CBGA Products on Sale Now (July 19, 2022)
    Hemp Inc.’s Chief Visionary Consultant Bruce Perlowin talks with Stock Day podcast about Hemp Inc.’s super potent line of CBD/CBG/CBN Products (July 7, 2022)
    Healthy Products for Healthy Living: A Look into Hemp, Inc.’s Pure, Premium, and Potent CBD and Wellness Products (June 16, 2022)
    Hemp, Inc. Releases New High Potency CBD/CBG Vanilla Flavored Coffee Enhancer (June 9, 2022)
    Hemp, Inc.’s King of Hemp CBD-CBG-CBN Natural Sleep Aid Capsules in Stock and On Sale (May 26, 2022)
    King of Hemp Natural and Vanilla-Flavored CBD/CBG “Super” Tinctures Now in Stock (May 12, 2022)

    The Company will continue to keep its shareholders up to date on all pertinent material events, product releases, production plans, and inventory availability. Those interested in distributing on a large-scale basis should email [email protected] or call 877-436-7564 for more information. The entire product line includes tinctures, gummies, capsules, and edibles in a variety of sizes, potencies, flavors, and formulas with a future focus on healthy foods for healthy living.

    Forward-Looking Statements

    This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. The Securities and Exchange Commission (SEC) requires issuers to provide “adequate current information”. Financials for Hemp, Inc. are listed on the OTC Exchange. More information can also be found on the Hemp, Inc. website by visiting www.hempinc.com/hemp-financial-disclosures/. The material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks and uncertainties.

    Contact: Hemp, Inc.
    [email protected] / (855) 436-7688
    Sales:(877) 436-7564

    Primary Logo

    Source: Hemp, Inc.

    2022 GlobeNewswire, Inc., source Press Releases

  • Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill

    Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill

    Las Vegas, NV, Nov. 22, 2022 (World NEWSWIRE) — by means of NewMediaWireHemp, Inc. (OTC PINK: HEMP): It is a new dawn, a new day as the first bill entirely relevant to marijuana is despatched to POTUS immediately after becoming approved by the U.S. Home and Senate – an unfathomable feat a ten years ago. Passed by unanimous consent, by the Senate, the marijuana-connected invoice alerts situations are modifying and so are perceptions about cannabis.

    Also numerous lives have been upended because of our failed technique to marijuana.  It is time that we suitable these wrongs. – President Joe Biden
    (Source: White Household Briefing Area)

    Right after yrs of championing legislation to legalize cannabis for professional medical uses, the H.R. 8454 – Health-related Cannabis and Cannabidiol (CBD) Analysis Growth Act marks a “historic breakthrough in addressing the federal government’s unsuccessful and misguided prohibition of cannabis.”

    In a assertion released by U.S. Congressman Earl Blumenauer (Founder and Co-chair of the Congressional Hashish Caucus and Sponsor of the Clinical Cannabis and Cannabidiol (CBD)  Research Act), “The public is worn out of ready for the federal authorities to catch up. Nearly half of our nation’s population now live in states in which grownup-use of hashish is lawful. For much also prolonged, Congress has stood in the way of science and development, producing barriers for researchers attempting to review cannabis and its added benefits. At a time when more than 155 million Americans reside where by adult-use of cannabis is legal at the point out or community level and there are four million registered healthcare marijuana consumers with many a lot more very likely to self-medicate, it is vital that we are able to fully analyze the impacts of cannabis use.” (Resource)

    Per Congress.gov, the Health care Cannabis and Cannabidiol (CBD) Investigation Expansion Act will:

    Set up a new, individual registration system to facilitate investigation on marijuana.

    Specially, the bill directs the Drug Enforcement Administration (DEA) to comply with specified treatments to register (1) practitioners to carry out marijuana study, and (2) makers to source cannabis for the investigation.

    The bill will allow specified registered entities (like institutions of greater instruction, practitioners, and makers) to manufacture, distribute, dispense, or possess cannabis or cannabidiol (CBD) for the needs of health care exploration. Moreover, the bill directs the DEA to register manufacturers and distributors of CBD or cannabis for the goal of commercial creation of an authorized drug that includes cannabis or its spinoff.

    Eventually, the invoice consists of a variety of other provisions, like provisions that:
    ·       demand the DEA to evaluate regardless of whether there is an ample and uninterrupted provide of marijuana for study purposes
    ·       prohibit the Division of Wellness and Human Solutions (HHS) from reinstating the interdisciplinary evaluate course of action for cannabis study
    ·       make it possible for doctors to examine the potential harms and benefits of marijuana and its derivatives (including CBD) with patients and
    ·       need HHS, in coordination with the National Institutes of Health and suitable federal agencies, to report on the therapeutic probable of cannabis for numerous disorders such as epilepsy, as very well as the effects on adolescent brains and on the capacity to run a motor vehicle. (Source: Congress.gov)

    In a nutshell, the Healthcare Marijuana and Cannabidiol (CBD) Analysis Enlargement Act will permit a much more streamlined approach to the software procedure for marijuana scientific studies and will take out the limitations that slowed down the course of action. Research on CBD and other potentially effective marijuana-derived substances will be centered on seem science without having any regulatory hindrance. Sure, there is evidence suggesting marijuana is helpful in managing glaucoma and epilepsy.  But as Congressmen Andy Harris stated, “Only scientific analysis will confirm the veracity of the numerous promises concerning efficacy for other conditions. Despite missing substantially scientific investigation, over a few dozen states have by now legalized health care cannabis, and the American community justifies to know the effect modern day marijuana has on the human entire body.” 

    When the bill formally reaches President Joe Biden’s desk, he will have 10 days (excluding Sundays) to sign or veto it.  A White Household spokesperson verified President Biden intends on signing the laws. The moment it is signed and enacted, the cannabis industry could see a flurry of marijuana-linked expenses.  MJ Biz Everyday reported there are “roughly 50 marijuana-associated expenditures circulating in Congress” with the Safe Banking Act (a proposed regulation that will allow state-authorized dispensaries to access banking services) predicted to have the most effective chance of passage.  Congressman Blumenauer believes the impending enactment of the Medical Marijuana and Cannabidiol (CBD) Exploration Expansion Act could present the momentum essential to push it as a result of Congress.

    Why is the Healthcare Cannabis and Cannabidiol (CBD) Investigation Expansion Act significant? Just after many unsuccessful makes an attempt from earlier expenditures, what propelled this a single to the President’s desk for signature? It’s the first legislation to unite opponents and proponents of hashish legalization. Both of those sides want extensive analysis accomplished, albeit for different reasons nevertheless. (Resource)

    In accordance to an posting in Cardinal News, opponents want proof that marijuana is dangerous and proponents want evidence that it is handy for professional medical purposes. A myriad of inquiries requirements responses. Do we will need a surgeon general’s warning? How can marijuana-derived medications treat different overall health conditions? These are just a couple of issues scientists have not been equipped to reply simply because cannabis is a Agenda 1 managed substance with bureaucratic hurdles and security measures deterring “would-be researchers” from discovering the solutions.

    This will not be the case a lot extended. A new dawn, a new working day is below for federal hashish reform. And as Bruce Perlowin (Hemp, Inc.’s Chief Visionary Consultant) said again in 2015, “you simply cannot keep back again the tide”. As soon as the Healthcare Cannabis and Cannabidiol (CBD) Investigation Enlargement Act is signed into legislation by Biden, the doorway will be open for new, innovative therapies derived from hashish that will, with any luck ,, give people additional treatment method choices, according to Senate Greater part Leader Chuck Schumer.

    Right until then, test out Hemp, Inc.’s item lines containing CBD, CBDA, CBG, CBGA, and CBN (non-psychoactive compounds discovered in cannabis plants). CBD, in specific, is recognized for discomfort relief, peace, and panic relief. Including CBG to CBD is identified to improve agony relief and CBN is recognised for helping sleeplessness. When CBN is put together with CBD and CBG, the positive aspects include relaxation, and diminished anxiety and ache therefore aiding in a far better night’s rest. Hemp, Inc.’s item lines have received rave testimonials because of to the superior efficiency and powerful, authentic therapeutic dose. The organization employs a pharmaceutical-grade beta-cyclodextrin (a carbohydrate employed throughout the manufacturing procedure) which is merged with CBD and CBG for fast absorption and uptake. To buy these wonderful products and solutions, click listed here.

    About Hemp, Inc.
    With much more than 10 several years of working experience in growing and processing hemp in North The united states, Hemp, Inc. has an founded community of market industry experts in every single segment of the industrial hemp industry. Hemp, Inc.’s 85,000 sq.-foot facility on more than 9 acres in Spring Hope, N.C. is a person of the greatest industrial multipurpose hemp processing amenities in North America. Its mission of delivering eco-friendly alternatives that support make the earth a improved spot proceeds to flourish as the enterprise advancements an at any time-increasing portfolio of income and worth-making synergistic businesses. Hemp may perhaps be the salvation in retooling The usa for greener, much more sustainable domestic manufacturing.

    To capture up with the newest news on Hemp, Inc., be sure to look at out:

    Hemp Inc.’s Year to Date Revenue Enhance 315{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} In excess of Last Calendar year
    Hemp Inc. Experiences Third Quarter Benefits and Elimination of “Yield” Sign
    Hemp Inc. Reveals Breathtaking Benefits of its Hemp Study
    Hemp Inc. Applauds President Biden’s Approach to Pardon Men and women Convicted of Uncomplicated Cannabis Possession
    Hempcrete Accredited for U.S. Household Design
    Hemp Inc. See Considerable Maximize in Profits In excess of the Last 3 Quarters
    Worldwide Hemp Fiber Market place Climbing at an Yearly Charge of 6.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    Hemp, Inc. Offers CBD-CBG Topical Soreness Relief Roll-On
    Hemp, Inc.’s Chief Visionary Specialist Bruce Perlowin Provides Prospect to Hemp, Inc. (August 8, 2022)
    Hemp Inc.’s CBDA and CBGA Products on Sale Now (July 19, 2022)
    Hemp Inc.’s Chief Visionary Expert Bruce Perlowin talks with Stock Working day podcast about Hemp Inc.’s super powerful line of CBD/CBG/CBN Merchandise (July 7, 2022)
    Healthy Products for Wholesome Dwelling: A Look into Hemp, Inc.’s Pure, Quality, and Powerful CBD and Wellness Goods (June 16, 2022)
    Hemp, Inc. Releases New High Potency CBD/CBG Vanilla Flavored Espresso Enhancer (June 9, 2022)
    Hemp, Inc.’s King of Hemp CBD-CBG-CBN Natural Sleep Aid Capsules in Inventory and On Sale (May 26, 2022)
    King of Hemp Organic and Vanilla-Flavored CBD/CBG “Super” Tinctures Now in Stock (May 12, 2022)

    The Organization will carry on to hold its shareholders up to day on all pertinent product activities, solution releases, generation options, and stock availability. Those people interested in distributing on a huge-scale foundation should email [email protected] or phone 877-436-7564 for a lot more information and facts. The entire product line features tinctures, gummies, capsules, and edibles in a wide variety of sizes, potencies, flavors, and formulation with a foreseeable future target on healthful food items for nutritious dwelling.

    Ahead-Hunting Statements

    This press launch may include sure forward-wanting statements and information, as described inside the indicating of Area 27A of the Securities Act of 1933 and Part 21E of the Securities Exchange Act of 1934 and is subject to the Risk-free Harbor established by people sections. The Securities and Exchange Fee (SEC) requires issuers to supply “adequate existing information”. Financials for Hemp, Inc. are detailed on the OTC Trade. Additional details can also be uncovered on the Hemp, Inc. website by visiting www.hempinc.com/hemp-monetary-disclosures/. The product incorporates statements about envisioned foreseeable future activities and/or monetary success that are forward-seeking in nature and topic to hazards and uncertainties. These kinds of forward-looking statements include challenges and uncertainties.

  • Biden Will Sign Medical Marijuana Research Bill

    Biden Will Sign Medical Marijuana Research Bill

    President Joseph Biden will sign bipartisan legislation passed final 7 days to advance study into cannabis, in accordance to multiple media stories. The bill, known as the Medical Marijuana and Cannabidiol Investigate Expansion Act, was authorised by unanimous consent in the U.S. Senate after be handed by the Property of Associates in the course of the summer season.

    The laws is a significant milestone in cannabis policy reform, marking the first time a standalone cannabis measure has been authorised by the U.S. Congress. The bill necessitates the U.S. Lawyer Genera’s office environment to consider well timed motion on programs to perform scientific research with hashish that have been submitted to the agency for approval. The president’s intention to signal the laws was initial exposed by Bloomberg and later on verified by a White Residence spokesperson.

    “Yes he’ll signal it,” a White Residence spokesperson instructed Cannabis Moment in an e mail.

    U.S. Residence Handed Invoice In July

    Democratic Representative Earl Blumenauer of Oregon, the co-sponsor of the legislation in the Residence with Maryland Republican Agent Andy Hariss, observed the significance of the invoice just after the Senate voted to approve the evaluate on Wednesday.

    “After performing on the problem of cannabis reform for a long time, lastly the dam is starting to split. The passage of my Clinical Cannabis and Cannabidiol Investigate Enlargement Act in the Property and Senate represents a historic breakthrough in addressing the federal government’s unsuccessful and misguided prohibition of cannabis,” Blumenauer, the founder and co-chair of the Congressional Cannabis Caucus, explained in a assertion. “As we have witnessed in condition right after point out, the community is weary of ready for the federal governing administration to catch up. Extra than 155 million Americans—nearly fifty percent of our nation’s population—now reside in states in which grownup-use of hashish is lawful.”

    In July, the bill was passed in the Home of Representatives by a vote of 325 to 95. In the Senate, wherever the legislation was passed by unanimous consent on November 23, the bill was sponsored by Democratic Senator Dianne Feinstein of California, Iowa Republican Senator Chuck Grassley and Senator Brian Schatz, a Democrat from Hawaii.

    “For considerably far too prolonged, Congress has stood in the way of science and progress, making barriers for scientists trying to review hashish and its advantages,” Blumenauer ongoing. “At a time when a lot more than 155 million Us residents reside where by adult-use of hashish is authorized at the condition or local level and there four million registered clinical marijuana buyers with many far more most likely to self-medicate, it is critical that we are equipped fully analyze the impacts of cannabis use.”

    Invoice Eases Federal Constraints On Cannabis Analysis

    The invoice is intended to ease federal limits on scientific research into hashish, which is however categorised as a Timetable 1 managed compound. The legislation streamlines the application course of action for the acceptance of cannabis-connected scientific research, producing it less complicated for scientists to recognize the potential clinical benefits of cannabis. The measure also would make it a lot easier for scientists to request big quantities of cannabis for their scientific studies.

    Under the legislation, the U.S. attorney standard would be given a 60-day deadline to approve an application for cannabis investigation or post a request for added details to the research applicant. The monthly bill also involves provisions to really encourage the U.S. Food items and Drug Administration to guidance the advancement of cannabis-derived remedies.

    “There is considerable evidence that marijuana-derived medicines can and are giving significant health and fitness benefits. Our monthly bill will make it easier to analyze how these medications can treat different circumstances, resulting in far more individuals becoming equipped to effortlessly obtain safe remedies,” Feinstein claimed in a assertion. “We know that cannabidiol-derived medicines can be productive for problems like epilepsy. This bill will help refine latest medical CBD practices and develop essential new apps. Immediately after a long time of negotiation, I’m delighted that we’re finally enacting this monthly bill that will consequence in crucial investigation that could assistance tens of millions.”

    After the invoice officially lands on the president’s desk, he will have 10 times to signal the legislation or veto it. If he fails to act in that time, the measure will go into outcome devoid of Biden’s signature.